Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Citius Pharmaceuticals Inc
(NQ:
CTXR
)
1.152
+0.102 (+9.68%)
Streaming Delayed Price
Updated: 1:46 PM EDT, Aug 11, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,230,944
Open
1.090
Bid (Size)
1.150 (46)
Ask (Size)
1.160 (27)
Prev. Close
1.050
Today's Range
1.035 - 1.200
52wk Range
0.8306 - 2.350
Shares Outstanding
145,979,429
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
Today 7:17 EDT
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Today 7:11 EDT
Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch!
Via
InvestorPlace
Performance
YTD
-31.04%
-31.04%
1 Month
+27.45%
+27.45%
3 Month
+30.49%
+30.49%
6 Month
-26.18%
-26.18%
1 Year
-38.09%
-38.09%
More News
Read More
12 Health Care Stocks Moving In Friday's After-Market Session
July 22, 2022
Via
Benzinga
Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm
May 25, 2022
Via
Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market
May 07, 2022
Via
Get News
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 07, 2022
Via
Benzinga
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy
May 11, 2022
Via
Get News
Exposures
Product Safety
3 Reddit Stocks to Buy in May
May 08, 2022
Via
InvestorPlace
Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.
May 04, 2022
Via
AB Newswire
Exposures
Product Safety
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
May 04, 2022
Via
Viz Release
Exposures
COVID-19
Product Safety
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
April 06, 2022
Via
Benzinga
61 Biggest Movers From Yesterday
April 28, 2022
Via
Benzinga
First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
April 26, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 06, 2022
Via
Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
April 06, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 17, 2022
Via
Benzinga
Penny Stock Watchlist - Here Are My Five Top Picks
February 17, 2022
Via
Talk Markets
FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids
February 15, 2022
Via
Benzinga
Citius Pharmaceuticals: Q1 Earnings Insights
February 10, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
November 30, 2021
Via
Benzinga
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
September 10, 2021
Via
Benzinga
Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs
August 04, 2021
Via
Benzinga
Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?
July 20, 2021
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
July 02, 2021
Via
Benzinga
56 Biggest Movers From Friday
July 06, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.